Date added: 18 Mar 2014
2011 - Best Biotechnology Product: Prolia and XGEVA® - Amgen
Amgen’s discovery of a critical physiologic pathway that regulates bone metabolism led to a new approach for the treatment of bone loss and destruction. As a first-in-class RANKL inhibitor, denosumab constitutes a bench-tobedside therapeutic concept for a variety of bone diseases. Extensive and thorough clinical development programs supported approval of denosumab for the treatment of postmenopausal osteoporosis and the prevention of skeletal-related events across a variety of advanced cancers metastatic to bone.